MDXG Stock Recent News

Study adds to the Company's growing body of evidence and expands the understanding of the regulatory capabilities of its DHACM and LHACM allografts on the fibrotic process

Every investment category must answer the big question, why? For undervalued biotech stocks, it comes down to advantaging a supremely relevant sector without paying full price.

MARIETTA, Ga., June 26, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the appointment of Kim Moller to Chief Commercial Officer. Ms. Moller has been serving as the Company's Senior Vice President, Sales since August 2020.

MARIETTA, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences:

MiMedx Group, Inc. (NASDAQ:MDXG ) Q1 2024 Earnings Conference Call April 30, 2024 4:30 PM ET Company Participants Matt Notarianni - Head of Investor Relations Joe Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig Hallum Brooks O'Neil - Lake Street Capital Markets Anthony Petrone - Mizuho Carl Byrnes - Northland Capital Markets Swayampakula Ramakanth - H.C. Wainwright John Vandermosten - Zacks Operator Good afternoon and thank you for standing by.

Net Sales of $85 Million Grew 18% Year-Over-Year for the First Quarter First Quarter GAAP Net Income was $9 Million First Quarter Adjusted EBITDA of $19 Million, or 22% of Net Sales Management to Host Conference Call Today, April 30, 2024 , at 4:30 PM ET MARIETTA, Ga., April 30, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the first quarter 2024.

MARIETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, April 30, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.

Exclusive agreement provides MIMEDX with rights to commercialize 510(k) cleared, bovine-derived collagen matrix particulate that is indicated for the management of exudating wounds Exclusive agreement provides MIMEDX with rights to commercialize 510(k) cleared, bovine-derived collagen matrix particulate that is indicated for the management of exudating wounds

MiMedx Group, Inc. (MDXG) Q4 2023 Earnings Call Transcript

MARIETTA, Ga., Feb. 20, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management will participate in the TD Cowen 44th Annual Health Care Conference.